Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1986 Dec;54(3):882–885. doi: 10.1128/iai.54.3.882-885.1986

Influence of mouse genotype on passive systemic anaphylaxis by immune complexes.

A Portolés, J M Rojo, R Díaz
PMCID: PMC260253  PMID: 3096895

Abstract

The influence of mouse genotype on passive systemic anaphylaxis (PSA) by immune complexes was studied. PSA was induced by using Brucella abortus endotoxin as the antigen and rabbit anti-Brucella endotoxin antisera. Experiments using syngeneic mice as well as mice congenic for H-2 showed that the H-2 haplotype influenced the sensitivity of mice to PSA. Among the H-2 haplotypes studied, H-2b was the most sensitive, followed by H-2k and H-2d. Experiments using passive transfer of serum as well as the complement inhibitors suramin and flufenamic acid indicated that variations in complement levels under control of H-2 may be responsible for the effects described. Cyproheptadine, a blocker of serotonin and histamine receptors, and imidazol-alpha-ketoglutarate, an inhibitor of thromboxane synthesis, inhibited PSA, indicating that platelet aggregation, possibly mediated by activated components of the complement cascade, is an important feature in the development of PSA reactions in this system. Differences between strains for protection by cyproheptadine and for the effect of complement inhibitors indicated a role of early components of the classical pathway in this model.

Full text

PDF
882

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asghar S. S. Pharmacological manipulation of complement system. Pharmacol Rev. 1984 Dec;36(4):223–244. [PubMed] [Google Scholar]
  2. Baker P. J., Wilson J. B. Chemical composition and biological properties of the endotoxin of Brucella abortus. J Bacteriol. 1965 Oct;90(4):895–902. doi: 10.1128/jb.90.4.895-902.1965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brazenor R. M., Angus J. A. Actions of serotonin antagonists on dog coronary artery. Eur J Pharmacol. 1982 Jul 30;81(4):569–576. doi: 10.1016/0014-2999(82)90346-6. [DOI] [PubMed] [Google Scholar]
  4. Cochrane C. G., Koffler D. Immune complex disease in experimental animals and man. Adv Immunol. 1973;16(0):185–264. doi: 10.1016/s0065-2776(08)60298-9. [DOI] [PubMed] [Google Scholar]
  5. Cochrane C. G. The role of complement in experimental disease models. Springer Semin Immunopathol. 1984;7(2-3):263–270. doi: 10.1007/BF01893023. [DOI] [PubMed] [Google Scholar]
  6. Curman B., Ostberg L., Sandberg L., Malmheden-Eriksson I., Stålenheim G., Rask L., Peterson P. A. H-2 linked Ss protein is C4 component of complement. Nature. 1975 Nov 20;258(5532):243–245. doi: 10.1038/258243a0. [DOI] [PubMed] [Google Scholar]
  7. Devey M. E., Bleasdale K., Collins M., Steward M. W. Experimental antigen-antibody complex disease in mice. The role of antibody levels, antibody affinity and circulating antigen-antibody complexes. Int Arch Allergy Appl Immunol. 1982;68(1):47–53. doi: 10.1159/000233066. [DOI] [PubMed] [Google Scholar]
  8. Démant P., Capková J., Hinzová E., Vorácová B. The role of the histocompatibility-2-linked Ss-Slp region in the control of mouse complement. Proc Natl Acad Sci U S A. 1973 Mar;70(3):863–864. doi: 10.1073/pnas.70.3.863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ferreira A., Nussenzweig V. Genetic linkage between serum levels of the third component of complement and the H-2 complex. J Exp Med. 1975 Feb 1;141(2):513–517. doi: 10.1084/jem.141.2.513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fong J. S., Good R. A. Suramin--a potent reversible and competitive inhibitor of complement systems. Clin Exp Immunol. 1972 Jan;10(1):127–138. [PMC free article] [PubMed] [Google Scholar]
  11. Fukumoto S., Tanaka K. Protective effects of thromboxane A2 synthetase inhibitors on endotoxin shock. Prostaglandins Leukot Med. 1983 Jun;11(2):179–188. doi: 10.1016/0262-1746(83)90018-5. [DOI] [PubMed] [Google Scholar]
  12. Goldman M. B., Goldman J. N. Relationship of functional levels of early components of complement to the H-2 complex of mice. J Immunol. 1976 Nov;117(5 Pt 1):1584–1588. [PubMed] [Google Scholar]
  13. Henson P. M., Cochrane C. G. Immunological induction of increased vascular permeability. II. Two mechanisms of histamine release from rabbit platelets involving complement. J Exp Med. 1969 Jan 1;129(1):167–184. doi: 10.1084/jem.129.1.167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hosoi S., Shinomiya K., Mikawa H. The use of monoclonal antibodies in demonstrating the effect of antibody heterogeneity on immune complex size. Clin Immunol Immunopathol. 1984 Sep;32(3):378–386. doi: 10.1016/0090-1229(84)90281-2. [DOI] [PubMed] [Google Scholar]
  15. Lagarde M., Ghazi I., Dechavanne M. Effects of ticlopidine on platelet prostaglandin metabolism. Possible consequences for prostacyclin production. Prostaglandins Med. 1979 Jun;2(6):433–439. doi: 10.1016/0161-4630(79)90127-7. [DOI] [PubMed] [Google Scholar]
  16. Ortega M. P., Sunkel C., Armijo M., Priego J. G. Effects of etofibrate on platelet function: in vitro studies in human plasma. Thromb Res. 1980 Aug 1;19(3):409–416. doi: 10.1016/0049-3848(80)90269-8. [DOI] [PubMed] [Google Scholar]
  17. Portolés A., Rojo J. M., Díaz R. Cuantificación (por nomogramas) de parámetros fisiopatológicos en un modelo experimental de anafilaxia pasiva por inmunocomplejos. Rev Esp Fisiol. 1984 Sep;40(3):297–309. [PubMed] [Google Scholar]
  18. Rojo J. M., Portolés M. P., Ojeda G., Portolés A. Immunomodulatory activity of anti-atherogenic drugs: effects on blastogenesis, humoral response, delayed hypersensitivity and passive anaphylaxis by immune complexes. Immunopharmacology. 1985 Apr;9(2):109–116. doi: 10.1016/0162-3109(85)90006-2. [DOI] [PubMed] [Google Scholar]
  19. Sánchez-Crespo M., Alonso F., Egido J. Platelet-activating factor in anaphylaxis and phagocytosis. I. Release from human peripheral polymorphonuclears and monocytes during the stimulation by ionophore A23187 and phagocytosis but not from degranulating basophils. Immunology. 1980 Aug;40(4):645–655. [PMC free article] [PubMed] [Google Scholar]
  20. Vanham G., Bloemmen F. J., Ceuppens J. L., Stevens E. A. Influence of immune-complex size and antigen-antibody ratio on immune complex detection with monoclonal rheumatoid factor and C1q. J Clin Lab Immunol. 1984 Oct;15(2):63–68. [PubMed] [Google Scholar]
  21. Violi F., Alessandri C., Frattaroli S., Ghiselli A., Balsano F. Effects of ticlopidine on platelet function and blood coagulation. Thromb Haemost. 1982 Oct 29;48(2):166–168. [PubMed] [Google Scholar]
  22. WARD P. A., COCHRANE C. G. BOUND COMPLEMENT AND IMMUNOLOGIC INJURY OF BLOOD VESSELS. J Exp Med. 1965 Feb 1;121:215–234. doi: 10.1084/jem.121.2.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Wilson C. B., Dixon F. J. Quantitation of acute and chronic serum sickness in the rabbit. J Exp Med. 1971 Sep 1;134(3 Pt 2):7s–8s. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES